Alternatives to Milrinone Infusion in Heart Failure

Primary Alternatives

The American College of Cardiology and European Society of Cardiology suggest dobutamine (2-5 µg/kg/min) as the most commonly used alternative inotropic agent for acute decompensated heart failure, frequently the first-line choice in clinical practice 1, 2
Low-dose dobutamine is generally sufficient for hemodynamic support, though higher doses may produce tachycardia, ventricular arrhythmias, hypokalemia, and myocardial ischemia 1
The European Society of Cardiology recommends levosimendan as a potentially superior alternative to milrinone, particularly in patients with decompensated chronic heart failure 2, 4
Levosimendan works through calcium sensitization of troponin-C and produces significant vasodilation through ATP-sensitive potassium channels, with a hemodynamic response maintained over several days 2
In acute heart failure after myocardial infarction, levosimendan halved mortality during the first 72 hours compared to dobutamine, with this mortality benefit maintained over 6 months 4
Standard dosing for levosimendan is 3-12 µg/kg bolus over 10 minutes followed by 0.05-0.2 µg/kg/min infusion for 24 hours, with the loading dose omitted in hypotensive patients (SBP <100 mmHg) 2
Enoximone is an alternative phosphodiesterase-III inhibitor with similar inotropic and vasodilating properties to milrinone, maintaining effectiveness during beta-blocker therapy 2

The American College of Cardiology suggests intravenous dopamine at low doses (3-5 µg/kg/min) may improve renal blood flow and is frequently combined with higher doses of dobutamine 1, 2, 4
For patients with adequate blood pressure, vasodilators (nitroprusside, nitroglycerin) combined with loop diuretics represent an alternative approach that avoids the risks of inotropic therapy, particularly useful in decompensated chronic heart failure with preserved blood pressure 2

The European Society of Cardiology recommends milrinone over alternatives in patients on chronic beta-blocker therapy, as it maintains full efficacy while dobutamine does not 2, 3, 5
Milrinone is preferred in patients with pulmonary hypertension or right ventricular failure, as it directly reduces pulmonary vascular resistance 3, 5
Alternatives are preferred over milrinone in patients with coronary artery disease, as milrinone may increase medium-term mortality in this population 2
Dobutamine may be safer initially in hypotensive patients, as milrinone's vasodilatory effects can worsen hypotension 2, 3

The American College of Cardiology and European Society of Cardiology warn that long-term continuous or intermittent inotropic therapy outside of palliative care or bridge to transplantation/LVAD is harmful and increases mortality 1, 4, 5
All inotropic agents require continuous hemodynamic monitoring and ECG telemetry, with a target mean arterial pressure ≥65 mmHg regardless of agent used 2, 3, 5
If hypotension occurs with any agent, it can typically be reversed with isotonic crystalloid/colloid boluses or addition of vasopressors (norepinephrine or vasopressin) 3, 6